Profile data is unavailable for this security.
About the company
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
- Revenue in SEK (TTM)55.40m
- Net income in SEK-333.40m
- Incorporated2006
- Employees40.00
- LocationEgetis Therapeutics AB (publ)Klara Norra Kyrkogata 26STOCKHOLM 111 22SwedenSWE
- Phone+46 86797210
- Fax+46 86635725
- Websitehttps://www.egetis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XSpray Pharma AB (publ) | 0.00 | -216.42m | 1.01bn | 26.00 | -- | 1.58 | -- | -- | -5.96 | -5.96 | 0.00 | 15.37 | 0.00 | -- | -- | 0.00 | -29.09 | -23.48 | -30.93 | -25.08 | -- | -- | -- | -- | 5.93 | -18.44 | 0.1883 | -- | -- | -- | -58.92 | -- | -14.46 | -- |
| Curasight A/S | -63.58m | -68.66m | 1.07bn | 4.00 | -- | 43.19 | -- | -- | -1.13 | -1.13 | -1.07 | 0.3809 | -1.52 | -- | -- | -11,171,250.00 | -163.63 | -37.34 | -313.58 | -40.89 | -- | -- | -- | -- | -- | -16.54 | 0.00 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
| Cantargia AB | 308.69m | 139.93m | 1.26bn | 23.00 | 10.00 | 4.24 | 8.79 | 4.08 | 0.5068 | 0.5068 | 1.33 | 1.20 | 1.41 | -- | 164.02 | 14,031,360.00 | 63.91 | -56.56 | 80.65 | -63.93 | -- | -- | 45.33 | -- | -- | 76.55 | 0.00 | -- | -- | -- | 42.27 | -- | -- | -- |
| Nightingale Health Oyj | 49.89m | -196.24m | 1.41bn | 100.00 | -- | 1.44 | -- | 28.24 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Solar Foods Oyj | 203.14k | -113.37m | 1.48bn | 57.00 | -- | 6.55 | -- | 7,287.19 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Intellego Technologies AB | 770.81m | 294.66m | 1.55bn | 65.00 | 4.75 | 2.33 | 4.81 | 2.01 | 9.81 | 9.81 | 25.91 | 20.01 | 1.28 | 10.59 | 2.32 | 12,432,400.00 | 49.11 | 17.13 | 61.64 | 23.87 | 70.97 | 58.82 | 38.23 | 21.32 | 4.11 | 5.35 | 0.0617 | -- | 42.25 | 222.71 | 14.78 | -- | -- | -- |
| Thor Medical ASA | 93.16k | -54.88m | 1.65bn | 13.00 | -- | 3.68 | -- | 17,668.44 | -0.223 | -0.223 | 0.0004 | 1.36 | 0.0002 | -- | 0.0078 | 11,111.11 | -13.37 | -59.74 | -13.90 | -81.16 | -- | -- | -58,908.00 | -- | 8.78 | -- | 0.018 | -- | -- | -- | -659.00 | -- | -33.37 | -- |
| BioInvent International AB | 244.85m | -323.94m | 1.73bn | 124.00 | -- | 2.53 | -- | 7.07 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Devyser Diagnostics AB | 242.80m | -25.20m | 1.82bn | 115.00 | -- | 5.32 | 1,296.61 | 7.48 | -1.52 | -1.52 | 14.66 | 20.48 | 0.5262 | 1.40 | 5.53 | 1,839,394.00 | -5.64 | -10.61 | -6.60 | -12.04 | 81.96 | 80.33 | -10.71 | -28.67 | 2.27 | -2.03 | 0.1312 | -- | 28.12 | 27.53 | -14.74 | -- | 52.54 | -- |
| Egetis Therapeutics AB (publ) | 55.40m | -333.40m | 2.02bn | 40.00 | -- | 6.63 | -- | 36.52 | -0.9376 | -0.9376 | 0.1554 | 0.7725 | 0.0945 | 45.53 | 1.93 | 1,582,857.00 | -56.85 | -36.53 | -87.92 | -41.52 | 30.14 | 81.16 | -601.62 | -558.74 | 0.7971 | -45.06 | 0.249 | -- | -19.97 | -11.00 | -5.11 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -113.30m | 2.04bn | 5.00 | -- | 9.96 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Diamyd Medical AB | 348.00k | -182.46m | 2.31bn | 41.00 | -- | 10.23 | -- | 6,638.22 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
| Vicore Pharma Holding AB | 8.50m | -424.45m | 3.03bn | 36.00 | -- | 3.16 | -- | 356.34 | -1.85 | -1.85 | 0.0371 | 3.40 | 0.0134 | -- | 2.04 | 293,137.90 | -66.65 | -49.13 | -71.78 | -54.58 | -- | -- | -4,992.90 | -1,107.81 | -- | -35.34 | 0.00 | -- | -- | -- | 45.77 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Egetis Therapeutics AB (publ)'s reporting currency: Swedish Krona SEK
16.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2024 | 26.94m | 6.82% |
| Unionen (Investment Management)as of 31 Dec 2024 | 13.80m | 3.49% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 6.07m | 1.54% |
| Atle Fund Management ABas of 31 Dec 2024 | 5.78m | 1.46% |
| Swedbank Robur Fonder ABas of 30 Dec 2025 | 5.40m | 1.37% |
| SEB Funds ABas of 31 Dec 2025 | 2.14m | 0.54% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 1.22m | 0.31% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Nov 2025 | 1.20m | 0.31% |
| Amundi Asset Management SASU (Investment Management)as of 31 Dec 2025 | 673.03k | 0.17% |
| Skandia Investment Management ABas of 28 Nov 2025 | 663.49k | 0.17% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
